Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases (Q48109824)

8 February 2018

title

Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases (English)

1 reference

8 February 2018

1 reference

7

1 reference

8 February 2018

author name string

Elaine S Chan

1

1 reference

8 February 2018

Bruce R Pawel

2

1 reference

8 February 2018

Diana A Corao

3

1 reference

8 February 2018

Sriram Venneti

4

1 reference

8 February 2018

Pierre Russo

5

1 reference

8 February 2018

Mariarita Santi

6

1 reference

8 February 2018

publication date

26 March 2013

1 reference

8 February 2018

Pediatric and Developmental Pathology

published in

1 reference

8 February 2018

volume

16

1 reference

8 February 2018

issue

4

1 reference

8 February 2018

page(s)

272-277

1 reference

8 February 2018

Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome

cites work

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Glypican-3 expression in Wilms tumor and hepatoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status.

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Role for amplification and expression of glypican-5 in rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Malignant Rhabdoid Tumors Express Stem Cell Factors, Which Relate To the Expression of EZH2 and Id Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Rhabdoid tumors of the liver: Rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

Nonsense Mutation and Inactivation of SMARCA4 (BRG1) in an Atypical Teratoid/Rhabdoid Tumor Showing Retained SMARCB1 (INI1) Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2350/12-06-1216-OA.1

21 January 2018

Identifiers

DOI

10.2350/12-06-1216-OA.1

1 reference

8 February 2018

1 reference

8 February 2018